ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025
Prolonged hypercalcemia induced by teriparatide: a case report and literature review.
Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacovigilance insights into drug-induced hypercalcemia: evidence from the U.S. FDA Adverse Event Reporting System (FAERS) database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Teriparatide is indicated for the treatment of osteoporosis with a high risk of fractures. While transient hypercalcemia is a commonly reported side effect, we report a case of prolonged hypercalcemia associated with teriparatide. The patient was a 76-year-old female who had postmenopausal and glucocorticoid-induced osteoporosis on the background of rheumatoid arthritis since 2005. After failing treatment with etidronate, alendronate, and denosumab in view of minimal improvement in bone density and multiple fragility fractures, she was started on teriparatide on 5 May 2023. Serial serum calcium levels were all normal before the initiation of teriparatide. However, she was noted to have prolonged asymptomatic hypercalcemia after 3 months of teriparatide therapy, with a peak calcium level of 11.78 mg/dl on 27 September 2023. Teriparatide was discontinued since 27 September 2023 and normalization of serum calcium was noted on 31 October 2023.The cumulative effect of teriparatide from relative "overdosing" may be a contributing factor for prolonged hypercalcemia in our case, given she had a body mass index of 14.42 kg/m
Indexed as
Identifiers
40500389What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.